HDAC9 and cervical carcinoma: Almotaity et al. incorporated in axial position the HDACI 4-phenylbutyrate in platinum (IV) derivatives of carboplatin and found compound cis-trans-[Pt(CBDCA)(NH3)2(PBA)(bz)] to display higher efficacy than the standard chemotherapeutic agent and to have a negative effect on cellular basal HDAC activity in A431 human cervical cancer cells [106].